The Cancer Drug Parity Act H.R. 1730 / S. 741

CURRENT LEGISLATION:
The Cancer Drug Parity Act H.R. 1730/ S. 741has recently been introduced by Representatives Brian Higgins (D-NY-26), Brett Guthrie (R-KY-2), Doris Matsui (D-CA-6), Gus Bilirakis (R-FL-12)), and Senators Jerry Moran (R-KS), Tina Smith (D-MN), Chris Murphy (D-CT), and Roger Wicker (R-MS). The legislation requires private health insurance plans offering intravenous cancer drug benefits to provide parity in patient cost sharing for orally administered and self-injectable cancer drugs.

BACKGROUND:
  • ASCO strongly supports requiring private health insurance plans offering intravenous (IV) cancer drug benefits to provide parity inpatient cost sharing between traditional IV drugs and oral anticancer drugs
  • Scientific advancements increasingly allow oncologists to treat cancer with oral anti-cancer medications that often provide clinical advantages over traditional forms of cancer medication
  • Some health plans impose higher cost-sharing requirements (copayments, coinsurance, etc.) on cancer patients for oral cancer drugs

Act Now! Send a Letter!

First Name

Last Name

Home Address

Email